Drugs / TGFβ-B-15 peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05721846 | May 2023 → May 2026 overdue | malignant pancreatic neoplasm | Inna Chen, MD | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFβ-B-15 peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05721846 ↗ |
| Known as | TGFβ-15 | “TGFβ-15 peptide vaccine” NCT05721846 ↗ |
| Modality | Vaccine | “Vaccine (500 μl aqueous solution of 200 μg TGFβ-B-15 peptide mixed to an emulsion with 500μl Montanide ISA-51)” NCT05721846 ↗ |
| Route | Subcutaneous | “as s.c. injection” NCT05721846 ↗ |